ONC-392 Study is testing a new medicine called ONC-392 for people with certain types of cancer. This medicine is being looked at by itself and with another medicine called pembrolizumab. ONC-392 is an antibody that helps the immune system attack cancer cells. It works with a part of the immune system called CTLA-4, which usually helps keep the immune system in check. This study is checking if ONC-392 can help fight cancer without causing too many side effects.
The study will be done in different phases and parts to figure out the best dose and how well it works. People with advanced or spreading (metastatic) cancers like lung cancer, melanoma, or pancreatic cancer might be able to join. Participants will need to visit the study center for regular check-ups and treatments.
- Participants must be over 18 and have certain types of cancer.
- There are different study parts, some for ONC-392 alone and some with pembrolizumab.
- Each part aims to find out how safe and effective the treatment is.
Before joining, people should talk to their doctor and consider if they are ready for regular visits and possible side effects.